Wednesday, September 10 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Wednesday, September 10 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Tuesday, September 9 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Tuesday, September 9 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Wednesday, September 10 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Wednesday, September 10 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Tuesday, September 9 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Wednesday, September 10 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Wednesday, September 10 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Wednesday, September 10 2:45–3:30pm
Cardiology in Focus: Breaking Down the Latest Guideline Updates
Wednesday, September 10 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Wednesday, September 10 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Tuesday, September 9 3:30–4:15pm
Skin Deep: Tackling Everyday Dermatologic Cases in Primary Care
Wednesday, September 10 1:30–2:30pm
Updates in COVID Management and Emergencies in Outpatient ID Setting
Tuesday, September 9 7:30–8:30am
Keeping Up with the Guidelines: Notable Updates for Primary Care Clinicians
Tuesday, September 9 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Tuesday, September 9 1:30–2:30pm
Breakthroughs in Psychiatry: Emerging Treatments for Common Disorders
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- Information to come
- Amy Clouse, MD, FAAFP
- Speaker: Astellas Pharmacueticals; Stock Holder (publicly traded company): Eli Lilly; Novo Nordisk
- Anelyssa D'Abreu, MD, MPH, PhD
- Independent Contractor: Biogen, Cognition Therapeutics, Inc., Eli Lilly, and Janssen
- Oscar A. de Leon-Casasola, MD
- Information to come
- Stephanie Faubion, MD, MBA, FACP, NCMP, IF
- No relevant financial relationships disclosed
- Lisa M. Ferreira, MD, FOMA
- Speaker: Elil Lilly and Novo Nordisk Inc.
- Katherine E. Galluzzi, DO, CMD, FACOFP
- Advisor: Lilly
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Consultant: OptumRx, Premier, Inc.
- Aubrey J. Grant, MD, FACC
- Information to come
- Lawrence Herman, DMSc, MPA, PA-C, DFAAPA
- Speaker: Novo Nordisk
- Jonette Keri, MD, PhD
- Researcher: Galderma; Advisor: Orthodermatologics
- Paola Lichtenberger, MD
- No relevant financial relationships disclosed
- Lee A. Lindquist, MD, MPH, MBA
- Information to come
- Philip Schoenfeld, MD, MSEd, MSc
- Speaker: Ironwood Pharmaceuticals, Ardelyx Pharmaceuticals, Phathom Pharmaceuticals, AbbVie Pharmaceuticals; Consultant: Phathom Pharmaceuticals, Ardelyx Pharmaceuticals
- Charles Vega, MD, FAAFP
- Consultant: Boehringer Ingelheim, and Exact Sciences
- Shirah Vollmer, MD
- No relevant financial relationships disclosed
Other Disclosures
Pamela Kushner, MD, FAAFP (Reviewer): Speaker and Advisor for AstraZeneca, Boehringer Ingelheim, Corcept, GSK, Haleon, and Novo Nordisk; Speaker for Astellas, Bayer, Janssen, Lilly, and Phathom; Advisor for Abbott and Bausch/SALIX
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.